IMPAX Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) granted final approval of the coteries Abbreviated New Drug Application (ANDA) for a generic version of Wellbutrin® XL 150 mg Extendedrelease Tablets on Wednesday, November 26, 2008. GlaxoSmithKline drugstores Wellbutrin® XL for the management of depression. IMPAXs Global Pharmaceuticals division launched the product immediately following approval.

According to Wolters Kluwer good condition, U.S. sales of Wellbutrin® XL 150 mg tablets were approximately $950 million in the 12 months ended September 2008.

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical team applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in adding to the development of branded stock. IMPAX showrooms its generic concoctions through its Global Pharmaceuticals division and departments store its branded concoctions through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed vending partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more info, please see the clubs Web slot at impaxlabs.com.

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995